Table 4.
Key randomized clinical trials evaluating new antiretrovirals: first-line and second-line treatments
| Clinical trial | Treatment arms | Inclusion | Objective | Results |
| First-line treatment | ||||
| ADVANCE | TDF/FTC/EFV | Naïve | 48-week efficacy | 2019 |
| N = 1100 | TDF/FTC/DTG | (South Africa) | ||
| TAF/FTC/DTG | ||||
| NAMSAL | TDF/3TC/EFV400 | Naïve | 48-week efficacy | 2019 |
| N = 606 | TDF/3TC/DTG | (Cameroun) | ||
| ADVANZ-4 | ABC/3TC/DTG | Naïve | 48-week efficacy | 4Q17 |
| N = 108 | ABC/3TC/DRV/r | (Spain) | IRIS | |
| Second-line treatment | ||||
| WHRI 052 | 2NRTI + LPV/r | Switch | 48-week efficacy | 2018 |
| N = 300 | 2NRTI + DRV/r 400 mg | (South Africa) | ||
| DAWNING | 2NRTI + DTG | First-line failure | 48-week efficacy | 3Q17 |
| N = 612 | 2NRTI + PI/r | (International) | ||
| D2EFT | DTG + DRV/r | First-line failure | 48-week efficacy | |
| N = 610 | 2NRTI + DRV/r | (International) | ||
2NRTI, two nucleoside analogues; 3TC, lamivudine; DTG, dolutegravir; DRV/r, darunavir plus ritonavir; EFV, efavirenz; EFV400, efavirenz 400 mg; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; PI/r, protease inhibitor plus ritonavir; TAF, tenofovir alafenamide TDF, tenofovir disoproxil fumarate.